Immediate Impact
8 from Science/Nature 61 standout
Citing Papers
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Works of Peter Sportelli being referenced
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
2019
Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Peter Sportelli | 725 | 678 | 647 | 80 | 1.4k | |
| Stacey M. Fernandes | 796 | 550 | 578 | 78 | 1.5k | |
| Mollie E. Moran | 896 | 667 | 464 | 41 | 1.4k | |
| Daruka Mahadevan | 657 | 557 | 821 | 69 | 2.1k | |
| Kai Uwe Chow | 658 | 844 | 441 | 57 | 1.8k | |
| Kena C. Miller | 624 | 498 | 596 | 69 | 1.3k | |
| Gunnar Juliusson | 634 | 652 | 374 | 53 | 1.5k | |
| Darrin M. Beaupre | 410 | 561 | 491 | 49 | 1.4k | |
| Yvona Brychtová | 686 | 439 | 419 | 67 | 1.2k | |
| Priti Patel | 807 | 676 | 252 | 56 | 1.2k | |
| Thomas Melchardt | 477 | 386 | 371 | 92 | 1.4k |
All Works
Loading papers...